StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report report published on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ BLPH opened at $0.04 on Friday. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.46. The company has a market cap of $428,050.00, a PE ratio of -0.04 and a beta of 0.70. The stock’s 50-day moving average price is $0.04 and its two-hundred day moving average price is $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.